Information Provided By:
Fly News Breaks for February 7, 2018
SGEN
Feb 7, 2018 | 09:17 EDT
SunTrust analyst Yatin Suneja raised his price target on Seattle Genetics to $60 after a Q4 earnings beat on slightly higher than expected Adcetris sales and lower R&D expenses. Suneja keeps his Hold rating on Seattle Genetics, warning that the "full E-1 data at ASH suggest the market potential for Adcetris in this indication (1L cHL) could be rather limited".
News For SGEN From the Last 2 Days
There are no results for your query SGEN